Physical activity (PA) levels are low in patients with lung cancer. Emerging evidence supports the use of interventions to increase PA in this population. We aimed to (1) identify and synthesize outcome measures which assess PA levels in patients with lung cancer and (2) to evaluate, synthesize and compare the psychometric properties of these measures. A systematic review of articles from searches was conducted of five electronic databases and personal records. Eligible studies were those which assessed PA using either performance-based or patientreported measures. For aim 2, studies identified in aim 1 reporting on at least one psychometric property (validity, reliability, responsiveness or measurement error) were included. Two independent reviewers assessed eligibility and risk of bias with the COnsensus-based Standards for the selection of health status Measurement INstruments. Thirty-four studies using 21 different measures of PA were identified. Seventeen studies used performance-based measures. The Godin Leisure Time Exercise Questionnaire (GLTEQ) was the most frequently used patient-reported measure. Psychometric properties were reported for 13 of these measures and most frequently for movement sensors. Two studies reported on properties of the GLTEQ. Quality ratings for risk of bias were low. There is significant heterogeneity amongst studies regarding method of PA measurement along the lung cancer continuum. Greater consensus could be achieved by using a consensus approach such as a Delphi process. Future studies should include assessment of psychometric properties of the measurement tool being used. Currently, it is recommended where feasible, both performance-based and patient-reported measurements of PA should be undertaken.
INTRODUCTION
Physical activity (PA) is defined as 'any bodily movement produced by skeletal muscles that requires energy expenditure'. 1 The American College of Sports Medicine (ACSM) recommendations for PA in cancer survivors are in line with current recommendations for the healthy population; 150 min of moderate-intensity (or 75 min of vigorous-intensity) aerobic exercise and two to three resistance training sessions per week. 2 Those unable to meet these recommendations should aim to be as physically active as possible. PA levels are low in cancer survivors; 18% of UK cancer survivors meet current guidelines. 3 In an Australian study, 40% of patients with non-small cell lung cancer (NSCLC) met current guidelines at the time of diagnosis compared with 71% of healthy individuals. 4 Global data demonstrate that 77% of adults are sufficiently active. survival of 25.63 months in those performing ≥9 metabolic equivalent (MET) hours/week of PA compared with 12.89 months in those performing <9 MET h/ week. 7 Nine MET h/week is equivalent to walking at an average pace for 3 h/week. 8 Emerging evidence supports the use of PA interventions as a safe and feasible way of improving outcomes for patients with NSCLC. 9, 10 PA is measured either objectively or subjectively. Objective methods involving accelerometry are often cost prohibitive in a clinical setting. Cheaper options, such as pedometers, may not be accurate in chronic disease populations with slower walking speeds. 11 Self-reported methods are relatively quick and simple to perform, but may be subject to recall bias. 12 As the body of evidence supporting the use of PA interventions grows, development of a core set of outcomes is needed for the measurement of PA for both clinical and research purposes.
Reporting on the psychometric properties of outcome measures is important to determine their validity and reliability in lung cancer. The psychometric properties discussed in this review include validity (criterion and construct), reliability and responsiveness. For further details, readers are referred to the work of Portney and Watkins (Chapters 5 and 6) 13 and Appendix S1 (Supplementary Information).
The findings of this review will assist clinicians and researchers to determine the most appropriate outcome measures to use in the measurement of PA in patients with lung cancer. The COnsensus-based Standards for the selection of health status Measurement INstruments (COSMIN) guidelines and the Preferred Reporting Items for Systematic Reviews and Metaanalyses (PRISMA) guidelines (where appropriate) were used in the design and reporting of this review. 14, 15 The aims of this review are to (1) identify and describe outcome measures which have been used to assess the level of PA in patients with lung cancer and (2) evaluate, synthesize and compare the psychometric properties of each of these outcome measures.
METHODS

Protocol
The protocol for this systematic review was registered on the International Prospective Register of Systematic Reviews (PROSPERO) (registration number: CRD42015024909).
Eligibility criteria Studies
This review considered any type of quantitative study design. Peer-reviewed journal articles published in English from 1980 were included. Conference abstracts were excluded due to the inability to effectively evaluate risk of bias. Specifically, for aim 2, the review included studies which aimed to develop a new outcome measure or evaluate the psychometric properties of an existing outcome measure identified as part of aim 1.
Participants
Participants with any type of lung cancer, at any stage of disease were considered. A minimum of 50% of participants in the study were required to have lung cancer. Studies without original participant data (such as editorials and literature reviews) were excluded.
Outcomes
Outcomes of interest were outcome measures which, based on face validity, aimed to measure participant PA levels (performance-based or self-reported).
For aim 2, the outcomes of interest were the psychometric properties reliability (inter-rater/intra-rater), measurement error, criterion validity (concurrent/predictive), construct validity (hypotheses testing) and responsiveness of one of the outcome measures identified against aim 1 (Table 1 and Appendix S2 (Supplementary Information)).
Information sources, search and study selection
Prior to conducting this review, the Cochrane Library, Physiotherapy Evidence Database, COSMIN list of systematic reviews 16 and PROSPERO were searched to ensure no similar systematic reviews had been published. Five electronic databases were searched by one reviewer (C.L.G.) using a systematic, comprehensive and reproducible search strategy to identify all published studies (Fig. 1 ). Databases were accessed via The University of Melbourne. The last search was run on 10 April 2015.
The search terms used to search all databases were grouped into three categories according to (i) patient population, (ii) the method of measuring PA and (iii) the outcome of interest (see Appendix S2 (Supplementary Information)). These terms were adapted from a similar previously published systematic review on outcome measurement. 17 All studies identified by the search strategy were assessed based on title/abstract for eligibility against aim 1 and aim 2 by two independent reviewers (C.L.G. and L.E.; Fig. 1 ). Full-text versions of all relevant studies were obtained and read to ensure inclusion criteria were met. Consensus was required by both reviewers. Disagreements were settled by a third independent reviewer (L.D.). Agreement between reviewers was estimated with percentage agreement and kappa statistic using SPSS for Windows statistical software package (IBM SPSS Statistics Version 21.0.0, Armonk, NY, USA). References were stored in Review Manager (RevMan) (Version 5.3 Windows, The Nordic Cochrane Centre, Copenhagen, Denmark).
Data collection process and data items
A data collection form was specifically developed and used to extract data from studies by one reviewer (S.J.) and a second reviewer cross-checked the extracted data (R.A.). Data items extracted were adapted from the COSMIN generalizability checklist 15 (see Appendix S2 (Supplementary Information)). Collected data were stored in Microsoft Office Excel 2010 software spreadsheets (Microsoft Corp., Redmond, WA, USA).
Risk of bias of studies
Two independent reviewers (S.M.P./L.E.) evaluated the risk of bias using the four-point COSMIN checklist 18 for all studies included for aim 2 (measurement properties). This checklist was originally developed to assess the methodological quality of patient-reported outcome measures (PROMs); however, it has been suggested for use with non-PROM as well. 15 Four items from the checklist are not relevant to non-PROM. The item score was obtained by using the lowest score recorded for a question within that item.
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RESULTS
Study selection
The search identified 1783 studies. Assessment of title/ abstract and full text resulted in 34 articles, using 21 different outcome measures to assess PA being included (Fig. 1) . Of the 34 articles included against aim 1, 18 of these assessed measurement properties of the outcome measure and therefore also met the criteria for aim 2. A list of outcome measures was generated (Table 1) which included: six questionnaires, four methods of patient-report, seven accelerometers, two pedometers and whole-body indirect calorimetry. Excellent 
Aim 1 Study characteristics
The 34 included studies for aim 1 reported on 26 unique samples, consisting of a total of 4970 patients with lung cancer. The majority of studies were observational.
Lung cancer type and stage
More than half of the studies identified (19/34, 56%) involved only patients with NSCLC. Seven studies (21%) comprised a mixed sample of both NSCLC and small cell lung cancer (SCLC). Fourteen (41%) studies included subjects across the spectrum of disease stage (Tables 2, 3 and Appendix S3 (Supplementary Information)).
Study setting and timing
In 17 (50%) studies, data collection was conducted in the hospital outpatient clinic or laboratory setting. Three of these studies also involved inpatient data collection. 19, 21, 27 In seven (21%) studies, data were collected through the use of surveys either mailed to the participant's home or completed by telephone.
PA was measured pretreatment (surgery, chemotherapy or radiotherapy) in 11 (32%) studies. Two of these studies also measured PA post-operatively 31, 41 and one during and following chemotherapy or radiotherapy. 41 Eight (24%) studies involved patients who were currently undergoing treatment (chemotherapy, radiotherapy or targeted therapy). Post-treatment (surgery, chemotherapy or radiotherapy) measurements were reported by eight (24%) studies (Tables 2, 3 and Appendix S3 (Supplementary Information)).
Outcome measures identified
Two studies identified involved both performancebased and patient-reported measures of PA.
4,27
Performance-based outcome measures Seventeen (50%) studies measured PA objectively through the use of accelerometers, pedometers or whole-body indirect calorimetry. Seven different accelerometers and two different pedometers were used by these studies to measure PA ( Table 2 ). The watch-like wrist Actigraph (Ambulatory Monitoring Inc., Ardsley, NY, USA) was reported in four separate papers, three of which involved the same patient sample. [19] [20] [21] Accelerometers were used to measure PA levels in patients 
Physical activity measures in lung cancer
with lung cancer preoperatively, during treatment and post-operatively. Common outcomes reported include mean activity duration, peak activity, circadian cycle, sleep time, step count, time spent sitting/lying/standing, time spent in discrete activity levels (by METs) and energy expenditure. Duration of wear and minimum data requirements vary in the current literature. Accelerometers were commonly worn 24 h/day for 4-7 days (Table 2) .
Patient-reported outcome measures
Nineteen (56%) studies measured PA using patient self-reported questionnaires, surveys or diaries ( Table 3 ). The most commonly used questionnaire was The Godin Leisure Time Exercise Questionnaire (GLTEQ), or a modified version, being used in seven studies. 
Aim 2
Eighteen studies reported on at least one psychometric property of the outcome measure used to quantify PA. Twelve (67%) studies included in aim 2 involved performance-based methods of measurement (Table S1 , Supplementary Information).
Risk of bias
Percentage agreement between reviewers was excellent (89% (25/28), kappa = 0.801), with the third independent reviewer required on three occasions to resolve reviewer disagreements. A summary of quality ratings for each psychometric property reported is provided in Table S2 (Supplementary Information). Overall quality ratings were predominantly fair or poor. Studies reported on construct validity (n = 16), criterion validity (n = 5), responsiveness (n = 5), reliability (n = 1) and internal consistency (n = 1). Of the 16 studies that reported on the construct validity of the outcome measure, 11 (69%) were rated 'fair' and five (31%) 'poor'. The item which most frequently received low ratings was related to the adequate reporting of the measurement properties of the comparator instrument. Ratings for criterion validity were variable with one study being rated excellent. 
Performance-based measures
Of the studies which reported on the psychometric properties of performance-based measures of PA, the majority provide evidence of construct validity by means of hypothesis testing (11 studies). Four studies provide evidence of responsiveness, one of predictive validity and one of criterion validity (through comparison with the gold standard). 
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Psychometric properties are reported for Actigraph, ActivPAL (PAL Technologies Ltd., Glasgow, UK), KinetaMap (Sparkfun Electronics GPS-08725, Boulder, CO, USA), Sensewear (SenseWear Pro3, APC Cardiovascular Ltd., Crewe, UK) and Lifecoder (Lifecoder EX, Suzuken, Co., Ltd., Nagoya, Japan) accelerometers. Responsiveness and construct validity are reported for the OMROM pedometer. 31, 32 In the only study identified to use the 'gold standard' measure of PA, whole-body indirect calorimetry, the bicarbonate-urea tracer method predicted CO 2 production and energy expenditure close to that of the gold standard. 34 Further details are provided in Appendix S3 and Table S1 (Supplementary Information).
Patient-reported measures
Seven studies used patient-reported methods to assess PA level. Again, the majority of studies reported evidence of construct validity through hypothesis testing. Two of these reported on the GLTEQ, finding moderate correlations between higher activity levels and quality of life (QoL). 40 There was a trend towards improved median survival in those who reported ≥9 MET h/week compared with their less active counterparts. 7 The PASE Questionnaire is reported to have moderate convergent and construct validity, be responsive to change and, when performed at diagnosis, is predictive of future physical function. 41 Further details are provided in Appendix S3 and Table S1 (Supplementary  Information) .
DISCUSSION
This review identified 34 studies measuring PA in 21 different ways in 4970 patients with lung cancer. The majority of studies were observational in nature, with 19 prospective cohort and 12 cross-sectional studies. Numerous variables contributing to the heterogeneity within this body of evidence have been identified. These include lung cancer type and stage, timing of measurement along the cancer treatment continuum and treatment type. Only one study collected data solely in the inpatient setting. PA has been measured in patients with lung cancer both preoperatively and post-operatively and also pre-, during and post-chemotherapy/radiotherapy or targeted therapy. Given previous observational work by our group has demonstrated a decline in self-reported PA from diagnosis to 6-month follow-up, 4 we would recommend measuring PA across all stages of the cancer treatment continuum.
Fifty percent of included studies reported on performance-based measures of PA through use of seven types of accelerometers, two types of pedometers and one study of whole-body indirect calorimetry and a tracer method. The most commonly used accelerometer was the watch-like wrist Actigraph (Ambulatory Monitoring Inc.), which was reported by four studies comprising two patient samples. [19] [20] [21] [22] Outcomes reported from these different devices varied significantly, including mean duration of daytime activity, peak activity, mean activity (accelerations per minute), sleep/activity cycles, daily or weekly step count, step rate, time spent sitting/lying/standing, time spent in activity categories according to MET levels, total energy expenditure and distance walked. Fifty-six percent of included studies used patient-reported measures. The most frequently used PROM was the GLTEQ, being reported in seven studies of five patient samples. 7, [37] [38] [39] [40] 51, 53 Next commonly, the PASE was reported in two studies. 4, 41 Of note, ECOG-PS was used to measure PA in one study. 54 ECOG-PS is a five-point ordinal scale measure of physical function as distinct from a measure of PA levels. 55 The variability in reporting makes comparison of PA levels between different study samples difficult. Greater consensus regarding PA outcome reporting could be achieved by using an approach such as a Delphi process. Use of variables which can be compared across different studies is recommended (e.g. step counts or energy expenditure in METs). 56 Only two studies used both performance-based and patient-reported measures of PA. 4, 27 In a surgical population, Agostini et al. measured preoperative activity levels using an eight-point Likert scale questionnaire and then collected 4 days of post-operative accelerometer data. Preoperative PA level significantly predicted post-operative PA levels. 27 Granger et al. collected data using an accelerometer and the PASE Questionnaire. No significant difference in steps/day over time was found using the accelerometer; however, self-reported PA levels declined significantly. 4, 27 This finding highlights the importance of using both methods of measurement. Indeed, it may be that these two methods are measuring different constructs. Self-reported methods also take into account the patient's perception of their activity levels; this has been previously demonstrated in a population following critical illness. 57 Patient perceptions may be impacted by many factors, including stage along the cancer treatment continuum, level of social support and premorbid activity levels.
Few studies report on the psychometric properties of the measures. Most report construct validity through hypothesis testing of associations with other outcomes of interest (e.g. depression). The overall quality of these studies was generally poor to fair, indicating that findings should be interpreted with caution. Evidence of construct validity exists for the Actigraph, 19, 21, 22 ActivPaL, 23 Sensewear 27 and Lifecoder 28 accelerometers. The KinetaMap accelerometer demonstrated weaker evidence of construct validity. 26 Responsiveness of the ActivPaL, 24 Sensewear 27 and Lifecoder 28 devices was reported using step count changes over time. No other reporting of measurement properties for accelerometers was identified. The only pedometer with reported psychometric properties was the OMROM pedometer. The OMROM demonstrated construct validity and was found to be responsive to change and predictive of post-operative peak oxygen uptake. 31, 32 The bicarbonate-urea tracer method of measuring total energy expenditure was reported to be valid when compared with the gold standard of whole-body indirect calorimetry and showed excellent agreement with patient-reported PA levels. Few details of how patientreported PA data were obtained are provided by this study. 34 The GLTEQ was the most frequently used patient-reported measure identified by this review and for this reason we would recommend its use in future studies. Psychometric properties have only been reported in two studies involving the target population. These studies demonstrated moderate evidence of construct validity 40 and a trend towards predictive validity. 7 The study by Jones et al. was the only study in this review to receive an 'excellent' quality rating. 7 Future studies using the GLTEQ in the lung cancer population should include assessment of the measure's psychometric properties. The only study reporting on psychometric properties of the PASE Questionnaire provided evidence of moderate construct validity, responsiveness and predictive validity 41 -therefore, further investigation of the PASE in this population is warranted.
Given that patients with lung cancer commonly present with co-morbidites such as COPD, 58 it may be possible to extrapolate findings from these populations to those with lung cancer. Performance-based devices are validated more extensively in chronic disease populations 59, 60 and comparisons are made to the healthy population. 61 Accelerometers are reported as being more sensitive for detecting walking than pedometers. Dynaport (McRoberts BV, The Hague, The Netherlands), Actigraph GT3X (Actigraph LLC Pensacola, FL, USA) and Sensewear accelerometers are valid and responsive for measurement of PA in COPD. 59 Consideration needs to be given to appropriate duration of wear; reliability of measurements may be impacted by disease severity with less severe COPD stages requiring longer duration of wear. 60 Four weekdays of at least 8-h wear has recently been reported as optimal duration in COPD. 62 A limitation of this review may be that only articles published in English were eligible for inclusion. It is therefore possible that relevant studies were excluded. Publication bias is possible as studies included were only those identified through electronic database searching and published research from the authors' personal records.
In conclusion, whilst it would be ideal to be able to provide recommendations as to which outcome measures are most appropriate to use in which cohorts of patients with lung cancer (operable or inoperable) and at which time points along the cancer treatment continuum, this is not possible at this stage due to the lack of consistency in outcome measure tools used in the studies identified by this review.
Future studies should be designed to incorporate testing of psychometric properties of PA outcome measures in patients with lung cancer. This would provide more data upon which to make recommendations. Validation studies pertaining to the particular device being used also need to be conducted, as results from one device cannot be generalized to others and rapidly developing technology means new alternative devices are often available and used.
Ideally, both performance-based and patientreported PA measurements should be performed. We recommend researchers using both forms of measurement where possible, or apply performance-based measures to a subset of populations in studies reporting PA in large mail or telephone-based surveys.
We recommend greater consensus on the PA variables reported to enable further comparison between studies. This could be undertaken using a consensus approach such as a Delphi process where an expert panel review literature to suggest a core outcome set for measurement in lung cancer, including both performance and self-reported measures. If these are then implemented by researchers and clinicians, comparison of data across different studies will be possible. This will facilitate the current emerging field of study to use the best possible measure at the most appropriate time point to measure patient outcomes.
